Last reviewed · How we verify
BB-031
BB-031 is a small molecule that targets the PI3K pathway.
BB-031 is a small molecule that targets the PI3K pathway. Used for Metastatic breast cancer.
At a glance
| Generic name | BB-031 |
|---|---|
| Also known as | DTRI-031 |
| Sponsor | Basking Biosciences, Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BB-031 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways. This inhibition can lead to the reduction of cancer cell growth and proliferation.
Approved indications
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) (PHASE2)
- Study of BB-025, Alone and After BB-031, in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BB-031 CI brief — competitive landscape report
- BB-031 updates RSS · CI watch RSS
- Basking Biosciences, Inc. portfolio CI